Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Association between the XPG Asp1104His and XPF Arg415Gln polymorphisms and risk of cancer: a meta-analysis.

He XF, Liu LR, Wei W, Liu Y, Su J, Wang SL, Shen XL, Yang XB.

PLoS One. 2014 May 6;9(5):e88490. doi: 10.1371/journal.pone.0088490. eCollection 2014.

2.

Lack of association between XPG Asp1104His and XPF Arg415Gln polymorphism and breast cancer risk: a meta-analysis of case-control studies.

Ding DP, He XF, Zhang Y.

Breast Cancer Res Treat. 2011 Aug;129(1):203-9. doi: 10.1007/s10549-011-1447-9. Epub 2011 Mar 22.

PMID:
21424776
3.

Genetic Association between the XPG Asp1104His Polymorphism and Head and Neck Cancer Susceptibility: Evidence Based on a Meta-Analysis.

Jiang HY, Zeng Y, Xu WD, Liu C, Wang YJ, Wang YD, Wang YD.

Asian Pac J Cancer Prev. 2015;16(9):3645-51.

4.

Association between the XPG gene Asp1104His polymorphism and lung cancer risk.

Zhou B, Hu XM, Wu GY.

Genet Mol Res. 2016 Jun 10;15(2). doi: 10.4238/gmr.15027395.

5.

Methodological remarks concerning a recent meta-analysis on XPG Asp1104His and XPF Arg415Gln polymorphisms and breast cancer risk.

Peng Q, Lao X, Li R, Qin X, Li S.

Breast Cancer Res Treat. 2013 Jun;139(2):617-8. doi: 10.1007/s10549-013-2526-x. Epub 2013 Apr 26. No abstract available.

PMID:
23619551
6.

Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population.

Du H, Zhang X, Du M, Guo N, Chen Z, Shu Y, Zhang Z, Wang M, Zhu L.

Sci Rep. 2014 Oct 21;4:6700. doi: 10.1038/srep06700.

7.

Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.

Zhu ML, Wang M, Cao ZG, He J, Shi TY, Xia KQ, Qiu LX, Wei QY.

PLoS One. 2012;7(7):e36293. doi: 10.1371/journal.pone.0036293. Epub 2012 Jul 18.

8.

Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk.

Liu C, Yin Q, Hu J, Weng J, Wang Y.

Tumour Biol. 2014 Feb;35(2):1203-9. doi: 10.1007/s13277-013-1161-9. Epub 2013 Sep 6. Review.

PMID:
24061640
9.

Current evidences on the XPG Asp1104His polymorphism and melanoma susceptibility: a meta-analysis based on case-control studies.

Xu Y, Jiao G, Wei L, Wang N, Xue Y, Lan J, Wang Y, Liu C, Lou M.

Mol Genet Genomics. 2015 Feb;290(1):273-9. doi: 10.1007/s00438-014-0917-2. Epub 2014 Sep 18.

PMID:
25231183
10.

Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.

Bănescu C, Iancu M, Trifa AP, Dobreanu M, Moldovan VG, Duicu C, Tripon F, Crauciuc A, Skypnyk C, Bogliș A, Lazar E.

Tumour Biol. 2016 Jul;37(7):9357-66. doi: 10.1007/s13277-016-4815-6. Epub 2016 Jan 16.

PMID:
26779634
11.

DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.

Liu D, Wu HZ, Zhang YN, Kang H, Sun MJ, Wang EH, Yang XL, Lian MQ, Yu ZJ, Zhao L, Olopade OI, Wei MJ.

Mol Carcinog. 2012 Oct;51 Suppl 1:E83-93. doi: 10.1002/mc.21862. Epub 2011 Dec 27.

PMID:
22213216
12.

XPG Asp1104His polymorphism and gastrointestinal cancers risk: a meta-analysis.

Luo JF, Yan RC, Zou L.

Int J Clin Exp Med. 2014 Nov 15;7(11):4174-82. eCollection 2014.

13.

XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.

Xiang T, Kang X, Gong Z, Bai W, Chen C, Zhang W.

Cancer Chemother Pharmacol. 2017 Apr;79(4):791-800. doi: 10.1007/s00280-017-3280-2. Epub 2017 Mar 17. Review.

PMID:
28314991
14.

Association between XPG polymorphisms and stomach cancer susceptibility in a Chinese population.

Chen YZ, Guo F, Sun HW, Kong HR, Dai SJ, Huang SH, Zhu WW, Yang WJ, Zhou MT.

J Cell Mol Med. 2016 May;20(5):903-8. doi: 10.1111/jcmm.12773. Epub 2016 Jan 28.

15.

Association of xeroderma pigmentosum complementation group G Asp1104His polymorphism with breast cancer risk: A cumulative meta-analysis.

Xu XM, Xie LC, Yuan LL, Hu XL, Jin JQ, Niu YM.

Mol Clin Oncol. 2014 Nov;2(6):1177-1181. Epub 2014 Aug 11.

16.

XPG gene polymorphisms and cancer susceptibility: evidence from 47 studies.

Huang J, Liu X, Tang LL, Long JT, Zhu J, Hua RX, Li J.

Oncotarget. 2017 Jun 6;8(23):37263-37277. doi: 10.18632/oncotarget.16146.

17.

Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer.

Jeon HS, Kim KM, Park SH, Lee SY, Choi JE, Lee GY, Kam S, Park RW, Kim IS, Kim CH, Jung TH, Park JY.

Carcinogenesis. 2003 Oct;24(10):1677-81. Epub 2003 Jul 17.

PMID:
12869423
18.

XPG Asp1104His, XRCC2 Rs3218536 A/G and RAD51 135G/C Gene Polymorphisms and Colorectal Cancer Risk: A Meta-Analysis

Eskandari E, Rezaifar A, Hashemi M.

Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1805-1813.

19.

XPC Ala499Val and XPG Asp1104His polymorphisms and digestive system cancer risk: a meta-analysis based on model-free approach.

Yu G, Wang J, Dong J, Liu J.

Int J Clin Exp Med. 2015 Apr 15;8(4):6621-30. eCollection 2015.

20.

The Association Between XPG Gene Polymorphism and Gastric Cancer Risk.

Su Y, Yang C, Zhang Z.

Genet Test Mol Biomarkers. 2017 Oct;21(10):619-624. doi: 10.1089/gtmb.2017.0056. Epub 2017 Aug 23.

PMID:
28832189

Supplemental Content

Support Center